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Introduction
Urinary tract infections (UTIs) are among the most common infec-
tious diseases treated by physicians and are increasingly associat-
ed with antibiotic-resistant bacteria (1, 2). Although bacteriuria, 
the presence of bacteria in the urine, is a key feature of UTI, it also 
occurs frequently in the absence of symptoms. Bacteriuria seeded 
from the intestinal microbiome may self- resolve, progress to UTI, 
or persist asymptomatically, in which case antibiotic treatment 
is not recommended (3). Indeed, recent studies support the exis-
tence of urinary tract microbiomes in otherwise healthy individu-
als (4). Multiple lines of evidence suggest that the microbiome can 
prevent infections. Paradoxically, antibiotic treatment has been 
observed to increase the risk of subsequent UTIs (5) and to increase 
the risk of UTIs caused by atypical uropathogens such as Pseudo-
monas (6). Members of the family Enterobacteriaceae, particularly 
E. coli, inhabit the intestinal microbiome and are most commonly 
associated with asymptomatic bacteriuria and UTI. The early bac-
teriuric state from which UTIs can develop is poorly understood 
and challenging to study, but it is known that UTI-associated 
E. coli isolates frequently possess nonconserved genetic systems 
related to virulence (7, 8).
Prominent among virulence-associated adaptations in uro-
pathogenic E. coli (UPEC) isolates are siderophores, specialized 
metabolites able to bind extracellular Fe(III) ions for nutritional 
use in low-iron conditions (7, 9). High-affinity Fe(III) binding by 
siderophores helps bacteria resist host-mediated iron depriva-
tion, a prototypical example of nutritional immunity (10, 11). Sid-
erophores are widespread among medically important bacteria, 
which often express chemically distinctive siderophore types. A 
recent quantitative metabolomics study of E. coli isolates from 
patients with UTI revealed that the resident intestinal strain in 
each patient that successfully infected the urinary tract preferen-
tially secreted the siderophores yersiniabactin (Ybt) and salmo-
chelin (12). These results suggest that the early stages of ascending 
UTI are competitive and favor isolates with specific siderophore 
profiles. In this and other studies, Ybt, a siderophore encoded by 
the Yersinia high pathogenicity island (HPI), was associated with 
urinary tract virulence (7, 13–17).
The Yersinia HPI is a complex, 4-operon mobile genetic element 
encoding proteins involved in Ybt biosynthesis, import, and tran-
scriptional regulation. It is highly prevalent among clinical extrain-
testinal pathogenic E. coli isolates and is also found with varying 
frequencies in other Enterobacteriaceae, including the eponymous 
Yersinia pestis (18). Yersinia HPI genes are highly upregulated during 
UTI, and Ybt is detectable in patients’ urine specimens (12, 14, 17). 
Ybt, the recognized product of Yersinia HPI–positive bacteria to 
date, has been distinguished from other E. coli siderophores by its 
ability to form stable Cu(II) complexes. This broad-spectrum metal- 
binding property enables Ybt to scavenge Fe(III) for nutritional use, 
detoxify copper, and catalyze superoxide dismutation (14, 15, 19). 
The multiple functions of Ybt illustrate the importance of diverse 
metal ion interactions during microbial pathogenesis.
A hybrid nonribosomal peptide synthetase/polyketide synthase 
(NRPS/PKS) pathway encoded on the Yersinia HPI directs the bio-
synthesis of Ybt. There is remarkable natural diversity in microbial 
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biosynthetic block in UTI89ΔybtS was experimentally over-
come by chemical complementation with salicylate-supple-
mented medium. The metabolomic profiles from Ybt producers 
(WT and UTI89ΔybtS plus salicylate) and the Ybt nonproducer 
(UTI89ΔybtS) were compared using supervised principal compo-
nent analysis–discriminant analysis (PCA-DA) (Figure 1A). Uni-
form separation of these 2 groups along the y axis of the PCA-DA 
plot confirmed that extracellular metabolites can differentiate 
Ybt-producing from nonproducing strains (Figure 1A).
To identify the specific extracellular metabolites that distin-
guish Ybt producers from nonproducers, we performed a loadings 
plot analysis (Figure 1B). In this plot, features with the highest D1 
loading scores are most strongly associated with Ybt producers 
and are, therefore, candidates for follow-up analysis. Ybt in the 
metal-free form (apo) and bound to Al(III) were among the molec-
ular features with the highest loading scores, as expected (Table 1) 
(29). We also observed dihydroaeruginoic acid (Dha), a known 
metabolite of pyochelin-producing strains of P. aeruginosa (Table 1 
and Supplemental Figure 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI92464DS1) (30, 31). 
Dha is the free form of an early phosphopanthetheine-bound 
intermediate in both the pyochelin and Ybt biosynthetic pathways 
(20, 32). Unexpectedly, the molecular feature with the highest 
loading score was an ion with m/z 307, which is lower than apo-Ybt 
(m/z 482) (Figure 1B and Table 1). Like Ybt, the molecular feature 
at m/z 307, herein called escherichelin, was present in the WT and 
salicylate-complemented UTI89ΔybtS supernatants but entirely 
absent in ΔybtS supernatants. These results are consistent with the 
production of a previously unappreciated secreted metabolite by 
E. coli with an intact Yersinia HPI.
Clinical Enterobacteriaceae isolates coproduce escherichelin and 
Ybt. To determine whether escherichelin production is specific to 
UTI89 or is present in other bacteria encoding the Yersinia HPI, 
we measured its production in a series of clinical urinary isolates 
and model strains of the Enterobacteriaceae family (Figure 1C). 
The UPEC model strains UTI89 and NU14 produced both Ybt 
and escherichelin, whereas CFT073, a widely used UPEC mod-
el strain with known mutations in the Yersinia HPI, and the K12 
strain MG1655 produced neither (33). Klebsiella pneumoniae and 
Citrobacter diversus isolates that produced Ybt also produced 
escherichelin (Figure 1C). These observations suggest that esch-
erichelin production is pervasive among clinically significant Ybt- 
producing Enterobacteriaceae family members.
Escherichelin production is associated with early Ybt biosynthetic 
enzymes. The Yersinia HPI and other siderophore systems are regu-
lated by Fur, an iron-responsive transcription factor, such that Ybt 
biosynthesis is downregulated in iron-rich conditions. To deter-
mine whether escherichelin is similarly regulated, we measured 
its secretion in a high-iron medium (complete M63 supplemented 
with 16.2 mg/l ferric chloride) (34). The high-iron medium abol-
ished escherichelin production, suggesting that it is regulated by 
iron in a manner similar to that of Ybt (Figure 2A).
To better understand the relationship between escherichelin 
secretion and Ybt biosynthetic genes (Figure 2B), we screened 
a panel of Yersinia HPI gene deletion mutants for altered esche-
richelin production (Figure 2C). Mutants lacking the biosynthetic 
genes ybtS, ybtE, irp1, or ybtU do not produce Ybt (Supplemental 
NRPS/PKS systems, which are notable in infectious diseases as the 
source of antibiotics such as mupirocin, tetracyclines, and macro-
lides, but also the source of many virulence-associated siderophores 
such as pyochelin in Pseudomonas aeruginosa and mycobactin in 
Mycobacterium tuberculosis (20–22). NRPS and PKS pathways are 
characterized by their thiotemplating, assembly line mechanism, 
whereby all substrates and intermediates are covalently attached 
to phosphopantetheinylated carrier protein (CP) domains as they 
proceed through the catalytic domains of large, multimodular bio-
synthetic enzymes. The Ybt biosynthetic substrates are chorismate, 
3 molecules of cysteine, malonate from malonyl-CoA, and methyl 
groups derived from S-adenosyl-methionine (SAM). During Ybt 
biosynthesis, YbtS converts chorismate to salicylate (23), which is 
activated and transferred onto the first NRPS, HMWP2 (irp2), by 
YbtE. After condensing salicylate and 2 molecules of cysteine, the 
last intermediate synthesized by HMWP2 is transferred onto the 
hybrid NRPS/PKS HMWP1 (irp1), where malonate, another mole-
cule of cysteine, and methyl groups are incorporated. At this point, 
YbtU catalyzes an NADPH-dependent reduction of an HMWP1-
bound intermediate. Once the molecule is complete, Ybt is released 
from the final CP domain of HMWP1 by a terminal thioesterase 
domain (20, 24). Although Ybt biosynthesis has been elegantly 
characterized in vitro, an untargeted survey of this pathway’s prod-
ucts in bacterial culture has not been reported.
In this study, comparative metabolomic profiling revealed 
escherichelin, a newly appreciated cellular product of the Ybt bio-
synthetic pathway in E. coli and other urinary Enterobacteriaceae 
isolates. Structural characterization identified escherichelin as 
2-(2-hydroxyphenyl)-4,5-dihydro-[2,4]bisthiazolyl-4-carboxylic 
acid, (abbreviated as HPTT-COOH from hydroxyphenyl- 
thiazolyl-thiazolinyl-carboxylic acid), an Fe(III) chelator that was 
previously synthesized and found to inhibit pyochelin-mediated 
iron uptake in P. aeruginosa (25). Escherichelin purified from 
E. coli lacks the siderophoric activity of Ybt, but inhibits P. aerugi-
nosa growth in a pyochelin-dependent culture condition. Consis-
tent with this activity, we observed that P. aeruginosa minimizes 
escherichelin release compared with E. coli, despite generating 
the same biosynthetic precursors to escherichelin during pyoche-
lin biosynthesis. This bioactivity and its production during human 
E. coli bacteriuria raises the possibility that escherichelin may help 
human hosts avoid developing symptomatic UTIs from pyoche-
lin-producing organisms. Escherichelin was detectable in a human 
subject who was experimentally colonized with a derivative of the 
bacterial interference strain E. coli 83972 that has been studied in 
several human trials as a potential agent to prevent UTI (26, 27). 
These findings reveal how a second metallophore product of the 
Yersinia HPI biosynthetic system may participate in interspecies 
competition during polymicrobial bacteriuria.
Results
Metabolomic profiling identifies multiple Yersinia HPI–associated 
metabolites. To identify secreted metabolites associated with the 
Yersinia HPI, we used liquid chromatography–mass spectrom-
etry (LC-MS) to compare culture supernatants from UTI89, a 
Ybt-producing model UPEC strain (28), and its isogenic mutant 
UTI89ΔybtS that cannot perform the first committed step of 
Ybt biosynthesis, salicylate synthesis (12, 23). As a control, the 
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Escherichelin is HPTT-COOH. Multiple structural analyses were 
used to determine the chemical structure of escherichelin. These 
analyses were guided in part by previous in vitro investigations of 
Ybt biosynthesis that noted a product with a positive-ion m/z of 
307 that was identified as 2-(2-hydroxyphenyl)-4,5-dihydro-[2,4]
bisthiazolyl-4-carboxylic acid (abbreviated as HPTT-COOH from 
hydroxylphenyl-thiazolyl-thiazolinyl-carboxylic acid) (24, 41–44). 
HPTT-COOH is a truncated version of Ybt that arises when a 
biosynthetic intermediate (Figure 2B, top structure) derived from 
salicylate and 2 cysteines is released from the first NRPS protein, 
HMWP2 (irp2), and spontaneously oxidized. High-resolution MS 
of escherichelin yielded an exact mass of 307.0216 for the [M+H]+ 
ion, supporting an empiric formula of C13H10N2O3S2 (calculated 
mass: 307.0206 for C13H11N2O3S2+). To determine whether esche-
richelin is synthesized from salicylate, we chemically complement-
ed UTI89ΔybtS with 13C6-salicylate and analyzed the supernatant 
by LC-MS. Upon 13C6-salicylate complementation, escherichelin 
at m/z 307 disappeared, and a new molecular feature at m/z 313 
Figure 2) (23, 35–38). A mutant lacking the Yersinia HPI transcrip-
tional regulator ybtA also produces no Ybt (38, 39). Deletion of 
ybtT, a putative editing enzyme, exhibits an intermediate phe-
notype with reduced Ybt levels (Supplemental Figure 2) (37, 38, 
40). These isogenic mutants are not attenuated for growth in 
iron-restricted medium (38). Among Ybt-null strains, extracellu-
lar escherichelin was undetectable in the culture supernatants of 
UTI89ΔybtS, ΔybtE, and ΔybtA (the 2 early biosynthetic genes and 
transcriptional regulator, respectively). In contrast, escherichelin 
was detectable in supernatants from UTI89Δirp1 and ΔybtU, the 
late Ybt biosynthetic pathway deletion mutants (Figure 2C). Intra-
cellular escherichelin levels followed a trend nearly identical to 
that of the extracellular levels between strains (Supplemental Fig-
ure 3). Overall, these patterns favor biosynthesis, rather than cel-
lular export, as the major determinant of escherichelin secretion.
The requirement of early Ybt biosynthetic genes for escheriche-
lin production is consistent with it being a Yersinia HPI product. 
The observation that late biosynthetic mutants (UTI89Δirp1 and 
ΔybtU) produce escherichelin, but not Ybt, 
further suggests that escherichelin is a de 
novo metabolite and not a Ybt breakdown 
product. The diminished, but not absent, 
escherichelin levels in late biosynthesis 
mutants (UTI89Δirp1 and ΔybtU, Figure 
2C) mirror the diminished irp2 expression 
observed with analogous Y. pestis mutants 
(36, 37). Although the precise reason for 
this altered gene expression in the mutants 
remains unclear, it has been proposed that 
feedback regulation from a late biosyn-
thetic gene product is reduced, leading to 
the downregulation. The feedback regu-
lation is believed to be mediated by YbtA, 
a member of the AraC transcription factor 
family whose members typically respond to 
allosteric activation by metabolites.
Figure 1. Metabolomic analysis reveals escherichelin as an additional product of Ybt-producing E. coli. (A) Two-group PCA-DA of LC-MS data demonstrate 
consistent variance in the secreted metabolomes of the Ybt producers, WT UTI89 and UTI89ΔybtS chemically complemented with salicylic acid (SA), and 
the nonproducer UTI89ΔybtS. Each point indicates the average of 3 technical replicates. Five biological replicates were analyzed from each experimental 
group. (B) The PCA-DA loadings plot, where each point is a molecular feature identified in the LC-MS analysis, reveals a molecular feature with m/z 307 
(escherichelin) that best distinguishes Ybt producers from nonproducers. (C) LC-MS/MS chromatograms of escherichelin (left) and apo-Ybt (right) from 
culture supernatants of Enterobacteriaceae isolates grown in iron-restricted medium. All of the strains that produced Ybt also produced escherichelin.
Table 1. Molecular features with the highest loading scores are candidate small molecules 
associated with Ybt biosynthesis
Rank Loading scoreA m/z Retention time (min) Identification Ref.
1 0.393 307.0 15.8 escherichelin
2 0.234 224.1 12.8 Dha 30–32
3 0.203 295.0 17.1 apo-Ybt peak 2B 14
4 0.193 188.1 4.9
5 0.187 498.1 10.8
6 0.169 482.1 17.1 apo-Ybt peak 2 14, 19
7 0.152 313.0 7.3
8 0.143 506.1 11.6 Al(III)-Ybt 29
9 0.137 482.1 16.3 apo-Ybt peak 1 14, 19
10 0.129 295.1 16.4 apo-Ybt peak 1B 14
AThe loading scores come from the loading plot of the positive-ion LC-MS data (Figure 1B).  
BSource-decay fragment of apo-Ybt.
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respectively (Supplemental Figure 4). Together, the molecular 
formula from high-resolution MS, the MS/MS fingerprint, and 
the 1H-NMR chemical shifts support HPTT-COOH as the esch-
erichelin structure. Escherichelin corresponds to an oxidized 
form of a Ybt biosynthetic intermediate and is structurally simi-
lar to the P. aeruginosa siderophore pyochelin. Escherichelin and 
pyochelin differ in the oxidation state of their first heterocyclic 
ring, and pyochelin is also further modified by the reduction of 
the second thiazoline to a thiazole and by N-methylation (45).
Escherichelin binds Fe(III). Given that escherichelin is produced 
by a siderophore biosynthetic pathway, regulated by Fur, and retains 
some of the functional groups required for metal binding by Ybt and 
pyochelin, we assessed the ability of purified escherichelin to form 
an Fe(III) complex in aqueous solution with UV-visible spectrosco-
py. As reported in previous studies, Fe(III) addition caused notable 
shifts in the UV-visible absorption spectra of Ybt and pyochelin, 
consistent with the formation of Fe(III) complexes (19, 46, 47). The 
escherichelin UV-visible absorption spectrum was similarly shifted 
following exposure to equimolar Fe(III) (Figure 3D). Cu(II) addition 
caused a qualitatively distinct shift from Fe(III) (Figure 3D). These 
results demonstrate that escherichelin, like Ybt and pyochelin, is a 
bacterial metallophore that forms Fe(III) and Cu(II) complexes.
To determine whether escherichelin binds metal ions in a man-
ner similar to Ybt and pyochelin, we conducted quantum-based 
calculations using density functional theory (DFT). These calcu-
lations predict stable 1:1 and 1:2 complexes of Fe(III)-escheriche-
lin in a hexacoordinate octahedral geometry (Figure 3, E and F). 
In the 1:1 complex, Fe(III) is bound by the salicylate oxygen, the 2 
appeared at the same retention time, consistent with incorporation 
of the six 13C atoms (Figure 3, A and B). The empiric formula and 
heavy isotope labeling are consistent with a biosynthetic product 
derived from salicylate and 2 cysteines.
Information about the connectivity of escherichelin’s atoms 
was obtained using tandem MS (MS/MS) and 1H-NMR. MS/
MS of the escherichelin [M+H]+ ion yielded unique fragments 
arising from neutral losses of 46, 78, and 104 Da (Figure 3C). 
The 46-Da neutral loss is consistent with an equivalent loss of 
HCOOH (formic acid or sequential loss of H2O and CO) and 
supports the presence of a carboxylic acid. The atypical neu-
tral losses of 78 and 104 Da are consistent with equivalent 
cleavages through the thiazoline ring to lose neutral fragments 
containing the carboxylic acid and either nitrogen [M-78]+ or 
sulfur [M-104]+ (Figure 3A). To further investigate the struc-
ture, we performed one-dimensional 1H and two-dimensional 
1H correlation spectroscopy (COSY) NMR experiments. The 
chemical shifts and assignments were as follows: 1H NMR (500 
MHz, CDCl3, δ), 8.15 (s, 1H,-CH=); 6.97, 7.1, 7.4, and 7.63 (s, 1H, 
aromatic), 5.05 (m, ~1H, CH-COOH), and 3.2 (dd, 2H, -CH2). 
The 5.05 multiplet was partially obscured by a solvent impurity, 
preventing an accurate signal assignment. The chemical shifts 
at 6.97, 7.1, 7.4, and 7.63 ppm that each integrate to 1 proton and 
correspond to aromatic protons further support the presence of 
a salicylate-derived aromatic ring. A singlet at 8.15 ppm is con-
sistent with the vinylic proton of the thiazole, and coupled res-
onances at 3.2 and 5.05 ppm are consistent with the presence of 
the methylene protons and the C-H proton of the thiazoline ring, 
Figure 2. Escherichelin production is iron repressible and dependent on early Ybt biosynthetic enzymes. Escherichelin levels in culture supernatants 
were quantified by LC-MS/MS relative to a 13C-IS. (A) UTI89 grown in complete M63 medium with or without 16.2 mg/l FeCl3 (34). Data represent the mean 
of 3 replicates, with SD plotted. ***P < 0.001, by unpaired t test. (B) Schematic of the Ybt biosynthetic pathway. Black zig-zag line designates a phospho-
pantetheine group covalently attached to the biosynthetic enzyme. Green designates chemical moieties built by early biosynthetic enzymes (YbtS, YbtE, 
and HMWP2), and blue designates chemical moieties built by late biosynthetic enzymes (HMWP1 and YbtU). (C) Isogenic mutants of UTI89 in select genes 
of the Yersinia HPI grown in iron-restricted medium. Data represent the mean of 8 replicates, with SD plotted.
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ion coordination in the Fe(III)- and Cu(II)-escherichelin com-
plexes is similar to that observed for metal-Ybt complexes and 
Fe(III)-Pch (15, 19, 48, 50). These results support the idea that 
escherichelin is an Fe(III)-binding molecule.
Escherichelin does not support iron-dependent E. coli growth. 
To determine whether escherichelin, like Ybt, can promote iron- 
dependent growth in E. coli possessing Yersinia HPI-encoded trans-
port genes, we measured UTI89 growth in a previously described 
siderophore-dependent growth assay (Figure 3G) (16, 19). Addition 
heterocyclic nitrogens, and the carboxylic acid group in the equa-
torial positions and by 2 water molecules in the axial positions. 
In the 1:2 complex, the carboxylic acids of the 2 escherichelin 
molecules and water do not participate as ligands. Instead, the 
nitrogen atoms and phenolic oxygen atoms of 2 the escheriche-
lins occupy all of the liganding positions. Pyochelin binds Fe(III) 
in similar 1:1 and 1:2 complexes with the same ligands (48, 49). As 
with Ybt, escherichelin is also predicted to form a stable Cu(II) 
complex (Supplemental Figure 5). Overall, the calculated metal 
Figure 3. Identification of escherichelin as HPTT-COOH, a metallophore inhibitor of Pseudomonas iron uptake. (A) Multiple chemical characterizations 
identify escherichelin as HPTT-COOH, a compound shown to inhibit pyochelin-mediated iron uptake in Pseudomonas. The positions of 13C salicylate incor-
poration are indicated in green, while MS/MS neutral losses are indicated as dashed lines. (B) Mass spectra at the retention time for escherichelin from WT 
UTI89, UTI89ΔybtS, and 13C6-SA–supplemented UTI89ΔybtS culture supernatants revealed that 6 carbons in escherichelin are derived from salicylate. (C) MS/
MS product ion spectrum of escherichelin. The 46-Da neutral loss indicates the presence of a carboxylic acid group, and the 87- and 104-Da losses correspond 
to fragmentation within the thiazoline ring. (D) UV-visible absorption spectra of purified escherichelin incubated with equimolar FeCl3 or CuSO4. (E and F) DFT 
simulations of escherichelin bound to Fe(III) in a 1:1 (E) and 2:1 (F) complex. The simulations predict stable Fe(III)-escherichelin complexes with hexacoordi-
nate octahedral geometry. (G) UTI89 growth curve in the presence or absence of a ferric ion chelator (0.5 mM EDDHA) and/or ferric ion supplementation (1 μM 
FeCl3). Growth was monitored by OD at 600 nm (OD600). Data represent the mean of 3, with SD plotted. (H) PW5011 (pvdA-E02::ISlacZ/hah), a P. aeruginosa 
strain MPAO1 transposon mutant (55, 56) expressing pyochelin as its sole siderophore, was grown in succinate medium for 20 hours in the presence of increas-
ing escherichelin concentrations relative to vehicle control. Bacterial growth was quantified by enumerating CFU/ml and is expressed as a percentage of the 
vehicle control. Data represent the mean of 3, with the SEM plotted. *P < 0.01 and **P < 0.001, by 1-way ANOVA with Dunnett’s multiple comparisons test.
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of the iron chelator EDDHA to the test medium causes substantial 
growth restriction. As previously observed, addition of Ybt that 
has been preincubated with equimolar Fe(III) restores growth to a 
density comparable to that of the unchelated medium. In contrast, 
addition of escherichelin that has been preincubated with equimolar 
Fe(III) resulted in no significant growth enhancement (Figure 3G). 
Although both escherichelin and Ybt bind Fe(III), these results show 
a nonequivalent ability to support iron-limited growth. This discrep-
ancy may arise from differences in Fe(III) affinity or from differen-
tial recognition of the complexes by bacterial transport proteins.
P. aeruginosa growth inhibition by escherichelin. The deficient 
siderophoric activity of escherichelin raises the possibility that 
this molecule performs an alternative function. In prior work by 
Mislin et al., escherichelin (previously designated HPTT-COOH) 
was synthesized as a pyochelin analog (51) and found to act as a 
competitive inhibitor of pyochelin-mediated iron import through 
the TonB-dependent outer membrane transporter FptA in P. aeru-
ginosa (25, 51, 52). Escherichelin did not mediate iron uptake and 
inhibited Fe(III)-pyochelin transport through FptA with a Ki of 27 
nM. In silico docking simulations could rationalize these results 
through occupancy of the Fe(III)-pyochelin binding site of FptA 
by a 1:2 Fe(III)-escherichelin complex [Fe(III):escherichelin] (25, 
48). Given that escherichelin can bind Fe(III) in solution but does 
not possess canonical siderophoric activity, we hypothesized that 
it may be produced by UPEC to inhibit pyochelin uptake by com-
peting P. aeruginosa strains in the urinary tract.
To determine whether escherichelin can inhibit ferric pyo-
chelin uptake, we examined the effect of escherichelin on growth 
of the P. aeruginosa strain PAO1. Although pyochelin enhances 
P. aeruginosa growth during infections (53, 54), it is functionally 
redundant with pyoverdin, a second siderophore, during in vitro 
growth in standard culture media. Escherichelin addition to a 
defined, iron-restricted minimal medium caused a dose-depen-
dent reduction in growth of a pyoverdin-deficient P. aeruginosa 
mutant strain, PW5011 (Figure 3H) (55–57). These results are con-
sistent with the escherichelin-mediated inhibition of iron uptake 
in P. aeruginosa noted by Mislin et al. (25).
P. aeruginosa minimizes escherichelin production. Production of 
a P. aeruginosa iron uptake inhibitor from the enzyme-bound pre-
cursor hydroxyphenyl-thiazolinyl-thiazolinyl-S-ppant (Figure 2B, 
top structure) presents a potential paradox, because this enzyme-
bound species is also a biosynthetic intermediate of pyochelin 
(20). Escherichelin release from this intermediate in P. aeruginosa 
would be expected to autoantagonize pyochelin-mediated iron 
uptake. To determine whether P. aeruginosa minimizes esche-
richelin release relative to E. coli, we compared escherichelin pro-
duction between UTI89 and PAO1 in low-iron medium. Despite 
comparable growth of both strains and substantial pyochelin 
production by PAO1, extracellular and intracellular levels of esch-
erichelin were markedly lower in PAO1 than in UTI89 (Figure 4 
and Supplemental Figures 6 and 7). This may reflect selective pres-
sure on the P. aeruginosa pyochelin biosynthetic pathway to avoid 
Figure 4. Escherichelin release is suppressed in P. aeruginosa relative to E. coli. LC-MS/MS chromatograms of extracellular metabolites released from Ybt 
and pyochelin biosynthetic enzymes in the E. coli strain UTI89 (left) and the P. aeruginosa strain PA01 (right) cultured in iron-deficient media are displayed 
in the center. Chromatograms are identically scaled, except for P. aeruginosa pyochelin, which is at ×0.1 magnification. The accompanying illustrations 
depict the sequential release of Dha, escherichelin, pyochelin, and apo-Ybt from multidomain NRPS/PKS enzymes associated with early (green rectangles) 
and late (blue rectangles) biosynthesis of Ybt (left) and pyochelin (right). Thick black arrows designate the biosynthetic steps at which metabolite interme-
diates transfer from early to late proteins.
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inhibiting pyochelin-mediated iron uptake, as well as an opposing 
selective pressure on E. coli to suppress competing Pseudomonas 
strains in polymicrobial settings.
Escherichelin is produced during human E. coli cystitis. Entero-
bacterial bacteriuria may be a frequent occurrence in the human 
urinary tract and is frequently accompanied by other flora (58–60). 
When native enterobacteria in the microbiome are suppressed or 
eliminated by antibiotic treatment, P. aeruginosa UTIs become 
more frequent (6). Therefore, we hypothesize that escherichelin 
release during enterobacterial bacteriuria prevents P. aeruginosa 
UTI. To determine whether Enterobacteriaceae produce esche-
richelin in the human urinary tract, we used LC-MS/MS to detect 
escherichelin in urine from 18 patients with uncomplicated cystitis 
caused by Ybt-producing E. coli. Escherichelin was detectable in 
8 of the 18 samples (Figure 5A and Table 2). In four escherichelin- 
positive specimens, Ybt was undetectable. As expected, esch-
erichelin was undetectable in patients with cystitis caused by 
Gram-positive species (Staphylococcus saprophyticus or Enterococ-
cus sp.) or Ybt-null E. coli. These results demonstrate that E. coli 
can produce escherichelin in the human bladder.
Escherichelin is produced during experimental 
bladder colonization with an E. coli 83972 strain. The 
concept that one bacterial strain or species can pre-
vent infection by another — termed bacterial inter-
ference — has been of longstanding interest in infec-
tious diseases (61–63). In this context, an avirulent 
strain or species that outcompetes more pathogenic 
strains may be useful as a probiotic to prevent infec-
tions. E. coli 83972, which asymptomatically colo-
nized a young Swedish girl for over 2 years (64), has 
been used in multiple UTI prevention studies (26, 
27, 63, 65–70). Among these studies are anecdotal 
reports of protection against symptomatic P. aeru-
ginosa UTIs, including 1 patient with asymptomatic 
cocolonization of 83972 and P. aeruginosa that pro-
gressed to UTI following loss of 83972 (26, 66). 
E. coli 83972 possesses the Yersinia HPI (71, 72) 
and was observed to produce escherichelin in iron- 
restricted medium (data not shown).
To determine whether 83972 secretes esche-
richelin in the human urinary tract, we analyzed urine 
specimens following experimental colonization of 
catheter-dependent patients with an 83972-derived 
E. coli strain lacking the virulence-associated papG 
adhesin (E. coli HU2117) (27). Bladder colonization 
was established by inserting urinary catheters that 
had been precoated with E. coli HU2117. Longitudi-
nal urine specimens were available from 1 subject 
(104 days for subject 9) who became colonized with 
HU2117 and another subject who was unsuccessful-
ly colonized (51 days for subject 10). Both subjects 
showed evidence of polymicrobial urinary tract col-
onization during the collection periods. In subject 9, 
escherichelin was detected throughout the 57 days 
of documented HU2117 colonization, reaching a 
maximum on day 7 after catheterization (Figure 5B). 
P. aeruginosa was detected by culture in the urine on 
day 7 but was unassociated with symptoms and became undetect-
able in subsequent specimens (27). On day 76, HU2117 coloniza-
tion had ended, and the subject developed a febrile UTI caused by 
another E. coli strain, which was accompanied by detectable esch-
erichelin. Subject 10 was not colonized with HU2117 or any other 
E. coli strains after day 0, and escherichelin was undetectable in 
all specimens (Figure 5C). These results are consistent with esche-
richelin production by HU2117 in conditions in which P. aeruginosa 
is encountered, which may contribute to the ability of this strain to 
suppress symptomatic P. aeruginosa UTI.
Discussion
In this study, we used isogenic mutants in the Yersinia HPI and 
untargeted LC-MS–based metabolomics to identify a previously 
unappreciated biosynthetic product of bacteria carrying the Yersinia 
HPI. Escherichelin had previously been observed during the in 
vitro reconstitution of Ybt biosynthesis (24), but we now identify it 
as a physiologically relevant product of the Ybt biosynthetic path-
way. The name escherichelin was chosen to recognize its identifi-
cation as a natural product from pathogenic E. coli (escheri-) and its 
Figure 5. Escherichelin is produced during clinical E. coli UTI and experimental human 
colonization with the asymptomatic bacteriuria strain E. coli HU2117. (A) Representative 
LC-MS/MS chromatogram for escherichelin in urine from a patient with an uncomplicated 
UTI caused by a Ybt-producing UPEC strain (results from 18 urine samples are shown in 
Table 1). Escherichelin coeluted with the 13C-IS (green). Escherichelin was undetectable 
in urine from a patient with a UTI caused by a Ybt-nonproducing UPEC strain. (B and C) 
LC-MS/MS chromatograms for escherichelin in urine from subjects who were successfully  
(B) or unsuccessfully (C) colonized with E. coli HU2117. The days after insertion of the 
HU2117-coated study catheter are indicated on the left. Where microbiological culture data 
were available, the results are listed to the right of the chromatograms. The colonized sub-
ject (B, subject 9) was colonized with HU2117 for 57 days and then developed a febrile UTI 
caused by another strain of E. coli on day 76, after colonization had ended. On day 7,  
P. aeruginosa was also present in this subject’s urine. Escherichelin was detectable 
throughout the colonization period and during the symptomatic E. coli UTI. The noncolo-
nized subject (C) did not show a presence of HU2117 after day 0, when the study catheter 
was inserted, and escherichelin was not detected in the longitudinal samples. P. vulgaris, 
Proteus vulgaris; A. faecalis, Alcaligenes faecalis; O. anthropi, Ochrobactrum anthropi;  
B. bronchiseptica, Bordetella bronchiseptica; S. epidermis, Staphylococcus epidermidis.
Downloaded from http://www.jci.org on November 26, 2017.   https://doi.org/10.1172/JCI92464
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 0 2 5jci.org   Volume 127   Number 11   November 2017
ports an inhibitory mechanism based on occupancy of the pyo-
chelin-binding site with a 1:2 Fe(III)-escherichelin complex. Here, 
we experimentally confirmed that escherichelin forms an Fe(III) 
complex and found by quantum calculations that this complex 
favors the molecular geometry used in the docking model of Mis-
lin et al. (25). We also experimentally confirmed that escherichelin 
purified from E. coli inhibits P. aeruginosa pyochelin–dependent 
growth. Overall, the results are consistent with a noncanonical sid-
erophore function for escherichelin as an effector of interspecies 
bacterial antagonism. To our knowledge, this is the first report of a 
microbial natural product that is a direct inhibitor of a competing 
species’ siderophore transport system.
Multiple studies have implicated the pyochelin siderophore 
system in virulence (74–76), including genetic abrogation of pyo-
chelin-mediated iron uptake that diminished P. aeruginosa viru-
lence in murine infection models (53, 54). In this context, esch-
erichelin-producing Enterobacteriaceae at colonized devices or 
mucosal surfaces may prevent P. aeruginosa from progressing to 
symptomatic infection by chemically inhibiting pyochelin-medi-
ated iron uptake. This scenario may occur at epithelial surfaces 
during transient or persistent colonization of the urinary tract. The 
apparent ability of asymptomatic bacteriuria E. coli strain 83972 
(or its derivative HU2117) to produce escherichelin during exper-
imental human colonization is consistent with a model in which 
E. coli in the urinary tract secretes an antivirulence compound 
against P. aeruginosa (26, 27). Expression of the virulence-associ-
ated Yersinia HPI in colonizing Enterobacteriaceae such as E. coli 
strain 83972 may thus confer both risk (from Ybt production) and 
benefit (escherichelin production) to patients (77). Engineering an 
E. coli strain that colonizes the bladder and retains escherichelin, 
but not Ybt, production may be a desirable bacterial interference 
strategy in the future. Lack of a recognized asymptomatic bacteri-
uria mouse model and mouse-specific bacterial tissue tropisms in 
the urinary tract suggest that these future engineered strains may 
be best evaluated in human studies.
Whereas the Ybt and pyochelin biosynthetic machineries 
both generate the immediate enzyme-bound precursor to esch-
erichelin (Figure 2B, top structure), the pyochelin machinery in 
P. aeruginosa releases less escherichelin than does the Ybt machin-
ery in E. coli. This is consistent with the evolutionary hypothesis 
that the pyochelin biosynthetic pathway evolved to avoid auto-
inhibition of Fe(III)-pyochelin uptake. The architectures of these 
pathways provide a potential explanation for this difference in 
escherichelin production. Specifically, the escherichelin precursor 
in the Ybt pathway forms at the terminus of the first NRPS pro-
tein (HMWP2), where it must be transferred in trans to the second 
NRPS/PKS protein (HMWP1). In the pyochelin pathway, this same 
intermediate is instead passed in cis to a subsequent domain on the 
same protein (PchF). In the Ybt biosynthetic pathway, this handoff 
between proteins appears to be particularly susceptible to spon-
taneous hydrolysis, thereby allowing it to become a branch point 
in which the intermediate can proceed to form either escheriche-
lin or Ybt. In contrast, this immediate precursor to escherichelin 
may be less vulnerable to hydrolysis off the pyochelin biosynthetic 
machinery, because it does not occur at a handoff between pro-
teins. During pyochelin biosynthesis, Dha is passed in trans from 
PchE to PchF, and it is Dha, rather than escherichelin, that accu-
metal chelating properties (-chelin). Escherichelin may have elud-
ed discovery in the 20 years since the identification of Ybt because 
its reverse-phase chromatographic and UV-visible spectroscopic 
characteristics are nearly identical to those of Ybt, making them 
difficult to resolve. Although escherichelin lacks the siderophoric 
activity of Ybt, the fortuitous synthesis of escherichelin prior to the 
present discovery (51) and the demonstration of its ability to inhibit 
pyochelin-mediated iron uptake by P. aeruginosa (25) suggests an 
alternative functional rationale for escherichelin’s secretion by 
Enterobacteriaceae: to inhibit iron uptake in a competing species. 
This niche exclusion function is consistent with clinical observa-
tions regarding Pseudomonas UTI, asymptomatic bacteriuria, and 
protective influences of a healthy human microbiome.
Other microbes have demonstrated an ability to interfere 
with pyochelin function. Pseudomonas fluorescens can synthesize 
an enantiomeric form of pyochelin (enantio-pyochelin), which 
preserves the coordinating properties of pyochelin while resist-
ing FptA-mediated uptake by pyochelin-producing competi-
tor strains. The fungal commensal and opportunistic pathogen 
C. albicans suppresses pyochelin biosynthesis, interfering with 
P. aeruginosa virulence, but not colonization, in a murine model 
(73). A detailed study by Mislin et al. (25) revealed that escheriche-
lin acts as a drug-like inhibitor of pyochelin-mediated iron uptake. 
Specifically, escherichelin competitively inhibited radioactive 55Fe 
iron uptake through the pyochelin outer membrane transporter 
FptA, with a Ki of 27 nM. A molecular docking simulation sup-
Table 2. Escherichelin and Ybt prevalence in urine samples  
from patients with uncomplicated UTI
Patient  
no.
Causative  
species
Ybt-producing  
in culture
Escherichelin in 
urine sample
Ybt in  
urine sample
3 S. saprophyticus – – –
5 Enterococcus spp. – – –
2 E. coli + – –
4 E. coli + – –
8 E. coli + – –
12 E. coli – – –
14 E. coli + – –
15 E. coli + + +
17 E. coli + – –
24 E. coli – – –
33 E. coli + – –
39 E. coli + – –
41 E. coli + – –
43 E. coli + – –
51 E. coli + + –
54 E. coli ND + +
56 E. coli + + –
66 E. coli + + –
74 E. coli + + –
80 E. coli + + +
83 E. coli + – –
95 E. coli + + +
ND, strain did not grow in complete M63, so Ybt production in culture could 
not be determined.
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UFLC-coupled AB Sciex 4000 QTrap mass spectrometer with a Tur-
bo V electrospray ionization (ESI) source. The LC separation was per-
formed on an Ascentis Express phenyl-hexyl column (100 × 2.1 mm, 
2.7 μM; Sigma-Aldrich) with a 32-minute linear gradient from 2% A 
(HPLC-grade water plus 0.1% [v/v] formic acid; Sigma-Aldrich) to 
98% B (90% acetonitrile plus 0.1% [v/v] formic acid; EMD Millipore) 
at 0.35 ml/min. The MS was operated in positive ion–enhanced MS 
mode, scanning from 50 to 1,200 m/z. The quality control sample was 
injected first to precondition the column and every 10 samples there-
after to assess instrument stability.
MarkerView, version 1.2.0 (Sciex) was used for the generation of 
an aligned peak list and statistical analysis. The triplicate runs were 
averaged, and the data were Pareto scaled for supervised PCA-DA 
with 2 groups: (a) UTI89 and ΔybtS plus salicylate; and (b) ΔybtS. 
Candidate molecular features were identified on the PCA-DA loading 
plots and then verified by visual inspection of the LC-MS data.
Metabolite detection and quantification in bacterial culture. Esch-
erichelin, Dha, pyochelin, and Ybt were detected in culture superna-
tants and cellular extracts from UTI89, PAO1, and clinical Entero-
bacteriaceae strains by a multiple reaction monitoring (MRM) 
method on the Shimadzu Prominence UFLC-coupled AB Sciex QTrap 
4000 with MS/MS transitions for escherichelin (307.0/219.9), Dha 
(224.0/178.0), pyochelin (325.0/190.0), apo-Ybt (482.2/295.1), and 
Fe-Ybt (535.6/349.5) and a collision energy of 37 V. The above column, 
mobile phases, and flow rate were used with the following LC gradi-
ent: solvent B was held constant at 5% for 2  minutes, increased to 56% 
over 8 minutes, and then increased to 98% over 2 minutes, all with a 
flow rate of 0.4 ml/min.
Stable isotope dilution was used to quantify escherichelin levels. 
A 13C6-escherichelin internal standard (IS) was generated by culturing 
UTI89 ΔybtS in complete M63 minimal medium supplemented with 
50 μM 13C6-salicylate. For quantification of extracellular escheriche-
lin, strains were grown under iron-restricted conditions, as described 
above, and 1 ml of culture supernatant was spiked with 25 μl 13C6-esch-
erichelin IS and 6 μl FeCl3. The samples were incubated at room tem-
perature for 10 minutes, centrifuged at 15,996 g for 3 minutes, and 
extracted on C18 solid-phase extraction 96-well plates (United Chem-
ical Technologies) with 80% methanol (Sigma-Aldrich). Samples were 
then analyzed by the escherichelin-specific MRM, and escherichelin 
levels were assessed by taking the peak area ratio of the native isotope 
escherichelin to the IS 13C6-escherichelin. Viable CFU were measured 
to ensure that all strains grew to an equal final density.
Intracellular escherichelin was extracted from 50-ml cultures grown 
under iron-restricted conditions, as described above. The cultures were 
centrifuged at 7,412 g for 10 minutes to pellet the cells. The supernatant 
was discarded, and the cells were washed 3 times with 25 ml PBS (Sigma- 
Aldrich). The pellets were then resuspended in 1.2 ml ice-cold 80% meth-
anol, briefly vortexed, and incubated on dry ice for 30 minutes. After 
thawing, the samples were centrifuged at 15,996 g  for 10 minutes to pellet 
the cell debris. The supernatant was retained, and 800 μl acetonitrile was 
added. The mixture was incubated on ice for 15 minutes and then centri-
fuged at 15,996 g for 2 minutes to remove any remaining debris. 13C6-esch-
erichelin (10 μl) IS was added to 250 μl of each sample, and escherichelin 
levels were quantified by LC-MRM, as described above.
MS for escherichelin identification. A Shimadzu UFLC-coupled Agi-
lent 6550 Q-TOF mass spectrometer with a Dual AJS ESI ion source 
was used to determine the accurate mass, and therefore molecular for-
mulates in P. aeruginosa. Intriguingly, Dha has been shown to 
possess antimicrobial activity against fungal and bacterial species 
(31). Applied generally, this suggests that the NRPS/PKS path-
ways may evolve to segregate modules onto separate proteins at 
steps in the pathway where a “leak” yields a product that benefits 
the organism. Whether the branch point in Ybt biosynthesis that 
yields escherichelin and the similar branch points in other NRPS/
PKS pathways reflect uncontrolled “leaks” or regulated process-
es is unclear. Further biochemical and genetic characterization of 
these pathways may address this possibility.
Advances in MS and the application of powerful computational 
and statistical analyses to the data have led to the fruitful appli-
cation of metabolomics to secondary metabolism (78). MS-based 
metabolomics is enabling the rapid discovery of secondary metab-
olites from newly sequenced bacterial strains as well as novel 
products from well-studied pathways (79). This approach moves 
beyond the functional screens that were historically used to dis-
cover siderophores and other natural products. With this unbi-
ased approach, one is open to discovering any molecule that is 
chemically compatible with the instrumentation, regardless of the 
molecule’s function. Continued application of LC-MS–based 
metabolomics to other siderophore biosynthetic pathways will 
further our understanding of iron acquisition by pathogens.
Methods
Bacterial strains and culture conditions. The well-characterized, cysti-
tis-derived model UPEC strain UTI89 was used for these studies (28). 
The creation of the isogenic mutants in ybtS, ybtE, irp1, ybtU, ybtT, 
and ybtA was previously described (12, 38). UTI89 Δirp1/entB::kan 
was generated in the same manner, using the lambda red recombinase 
method (80, 81). For growth under iron-restricted conditions, strains 
were first grown in Luria-Bertani (LB) broth (BD Biosciences) over-
night at 37 °C under shaking conditions. They were then back-diluted 
1:1,000 into M63 minimal medium supplemented with 10 mg/ml nia-
cin and 0.2% (v/v) glycerol (Sigma-Aldrich; complete M63). For salicy-
late complementation experiments, 50 μM salicylate or 13C6-salicylate 
(Sigma-Aldrich) was also added. To achieve iron-replete conditions, 
16.2 mg/l FeCl3 (Sigma-Aldrich) was added to the complete M63. 
For comparison of E. coli and P. aeruginosa metabolites, the model 
P. aeruginosa strain PAO1 was used (82). In these experiments, UTI89 
and PAO1 were grown in complete M63 supplemented with 1% (w/v) 
casamino acids (BD Biosciences). For E. coli siderophore–dependent 
growth assays, the iron-limited and nutrient-rich yeast extract–casa-
mino acids (YESCA) medium was used (1% casamino acids and 0.12% 
yeast extract; BD Biosciences). All cultures were grown at 37°C under 
shaking conditions for approximately 18 hours. Other model E. coli 
strains (MG1655 [ref. 83], CFT073 [ref. 84], NU14 [ref. 85], and 83972 
[ref. 64]) as well as clinical isolates of UPEC, K. pneumoniae, and 
C. diversus were grown in the same manner.
Metabolomic analysis. For metabolomics experiments, 5 biological 
replicate cultures were cultivated from 5 distinct single colonies under 
iron-restricted conditions, as described above. Cultures were cen-
trifuged at 7,142 g for 10 minutes to pellet the cells. The spent super-
natants were collected and filtered through 0.22-μM filters (EMD 
Millipore). A quality control sample was generated by combining an 
equal volume of each sample. The samples were analyzed in techni-
cal triplicates and in a randomized order on a Shimadzu Prominence 
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a final concentration of 1 μM, and the cultures were grown at 37°C 
under shaking conditions. Bacterial growth was monitored over time 
by measuring the OD at 600 nm.
Escherichelin activity assay on P. aeruginosa. PW5011 (pvdA-E02::IS-
lacZ/hah) (55, 56) was grown in LB broth overnight at 37°C under shak-
ing conditions and then back-diluted into succinate medium (25) at 108 
CFU/ml. The growth experiments were performed in a final volume of 
100 μl in 96-well plates. Escherichelin, solubilized in ethanol, was add-
ed to the cultures at increasing concentrations. The final ethanol (vehi-
cle) concentration in all cultures was 5% (v/v). The cultures were grown 
at 37°C under shaking conditions for 20 hours, at which point they were 
serially diluted in PBS and plated on LB agar for CFU quantification.
Theoretical calculations. The theoretical calculations to identify 
thermodynamically stable escherichelin-metal complexes were per-
formed with the DFT method as previously described (15, 19). This 
DFT approach was previously used to model a structure of Fe(III)-
Ybt that matched the published crystal structure (50). The simulated 
Fe(III)-escherichelin complexes agree with a previously described 
model of Fe(III)-escherichelin bound to FptA (25).
Escherichelin detection in urine. The clinical uncomplicated cys-
titis isolates were grown under iron-restricted conditions, and their 
supernatants were analyzed for Ybt by LC-MRM. Seventeen of the 
nineteen selected isolates were Ybt producers. The 2 Ybt nonproduc-
ers were used as controls. Two additional strains (Staphylococcus sap-
rophyticus and Enterococcus sp.) were selected from the cohort to serve 
as non–E. coli, Ybt-negative controls. After determining whether the 
causative strain was a Ybt producer, the corresponding urine samples 
were thawed on ice and then centrifuged at 15,996 g for 3 minutes to 
remove any debris. To each 500 μl of urine, 12.5 μl 13C6-escheriche-
lin IS and 3 μl 0.5 M FeCl3 were added. The samples were incubated 
at room temperature for 15 minutes and then centrifuged at 15,996 g 
for 5 minutes. The supernatant was then extracted on 96-well C18 
solid-phase extraction plates with 80% methanol. Escherichelin was 
detected by LC-MRM using the method described above. Escheriche-
lin was detected in the bacterial interference trial specimens using the 
same extraction and LC-MRM methods.
Statistics. GraphPad Prism 4 (GraphPad Software) was used to 
perform statistical analysis and generate graphs for this study. All 
P values were determined by unpaired, 2-tailed t test or 1-way ANOVA 
with Dunnett’s multiple comparisons test. A P value of 0.05 or less was 
considered statistically significant.
Study approval. The urine and bacterial specimens from patients 
with uncomplicated cystitis were collected with the approval of the 
Human Subjects Review Committee of the University of Washington. 
All participants provided written informed consent for the sample collec-
tion and following analysis, prior to inclusion in the study. Study design, 
inclusion and exclusion criteria, and sample preparation were previously 
described (14, 86). β-Hemolytic E. coli isolates from urine cultures with 
105 or more CFU/ml were selected from the cohort for analysis.
The HU2117 experimental human colonization study protocol 
was approved by the FDA (investigational new drug [IND] 14007), 
the IRB of Baylor College of Medicine, and the Houston VA Research 
and Development committee and registered as a clinical trial (Clin-
icalTrials.gov identifier: NCT00554996. All participants provided 
written informed consent prior to inclusion in the study. The study 
design, inclusion and exclusion criteria, and specimen preparation 
were previously reported (27).
mula, of escherichelin in UTI89 supernatant that had been prepared as 
described above. LC separation was performed on an Ascentis Express 
phenyl-hexyl column (100 × 2.1 mm, 2.7 μM) with the same mobile 
phases as described above. The gradient was as follows: solvent B was 
held constant at 2% for 1 minute, then increased to 50% over 6 min-
utes, then increased to 98% over 2 minutes, and then held constant 
at 98% for 1 minute, all with a flow rate of 0.6 ml/min. The MS was 
operated in positive-ion mode, scanning a mass range from 75 to 1,100 
Da. The calculated mass for HPTT-COOH is [M+H]+ (C13H11N2O3S2+) = 
307.0206, and 307.0216 was found.
MS/MS was performed on the Shimadzu Prominence UFLC-cou-
pled AB Sciex QTrap 4000. Supernatant from UTI89 grown under 
iron-restricted conditions was prepared as described above for 
detection and quantification. Data were collected in the positive-ion, 
enhanced product ion (EPI) mode, with the parent ion m/z set at 307 
and the collision energy set at 37 V.
Escherichelin purification. Escherichelin was purified from 
UTI89Δirp1/entB::kan grown under iron-restricted conditions, as 
described above, with the addition of 20 μM 2,2′-dipyridiyl (Sigma- 
Aldrich) and 0.1% casamino acids (w/v) to the complete M63. Culture 
supernatant was applied to a methanol-conditioned C18 silica column 
(Sigma-Aldrich). The column was washed with water and then elut-
ed with 80% methanol. The eluate was dried down with a lyophilizer 
(Labconco), resuspended in 20% methanol, and further purified on 
a Bio-Rad BioLogic DuoFlow 10 system equipped with a QuadTec 
UV-Vis detector and a Kromasil Eternity-5-phenylhexyl column (Akzo-
Nobel). The column was run at 0.7 ml/min with water plus 0.1% for-
mic acid (solvent A) and acetonitrile plus 0.1% formic acid (solvent B) 
and the following gradient: solvent B held steady at 0% for 2.5 ml, then 
increased to 30% over 2 ml, then increased to 70% over 20 ml, and 
finally increased to 100% over 2 ml. Fractions containing escherichelin 
were identified via UV-Vis detection at 318 nm, pooled together, and 
dried down by lyophilization. Purification was confirmed by LC-MS.
NMR. Purified escherichelin was resuspended in CDCl3. One- 
dimensional 1H and two-dimensional 1H COSY spectra were collected 
at 20°C on a Varian Unity Inova-500 MHz instrument.
UV-Vis spectroscopy. Purified escherichelin was reconstituted to 
1 mM in 50% ethanol (Sigma-Aldrich). For experiments to monitor 
metal binding, escherichelin was diluted to 100 μM in water and 
combined with an equimolar amount of FeCl3 or CuSO4 (Sigma- 
Aldrich). The samples were incubated at room temperature for 2 
hours, and then a wavelength scan was collected from 200 to 800 
nm on a UV-Vis spectrophotometer (Beckman Coulter; DU800). For 
each escherichelin-plus-metal scan, the instrument was blanked with 
a metal-only control. For escherichelin alone, the instrument was 
blanked with 5% ethanol.
E. coli siderophore–dependent growth assay. The assay was adapt-
ed from a previously published Fe(III)-Ybt–dependent growth assay, 
and apo-Ybt was purified as previously described (16, 19). UTI89 was 
grown overnight in LB broth at 37°C under shaking conditions and 
then washed 3 times by centrifugation and resuspension in a volume of 
PBS equal to the culture volume. The washed bacteria were inoculated 
1:100 into YESCA or YESCA supplemented with 0.5 mM ethylene-
diamine-N,N′-bis(2-hydroxyphenylacetic acid) (EDDHA; Complete 
Green Company). Prior to their addition, apo-Ybt and escherichelin 
were preincubated for 2 hours with an equimolar amount of FeCl3 to 
allow for complex formation. The Fe(III) complexes were added at 
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